Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling the GLP‑1 ...
For the quarter ended December 31, 2025, ResMed reported adjusted earnings per share of $2.81, exceeding analyst estimates of $2.73. Revenue increased 11% to $1.4 billion, in line with consensus ...
We came across a bullish thesis on ResMed Inc. on Best Anchor Stocks’s Substack. In this article, we will summarize the bulls ...
ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business ...
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ...
For those who wear continuous positive airway pressure (CPAP) masks -- which help people with sleep apnea maintain steady, regular breathing while asleep – a new app is designed to help support device ...
As Philips stares down an international recall of more than 2 million of its CPAP and sleep apnea machines, the respiratory devicemaker ResMed is looking to pick up the slack—but the surge in demand ...
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results